Cesca Therapeutics, Inc. is engaged in research, development and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, cell manufacturing and banking markets. KOOL offers SurgWerks, a leading therapeutic technology platform, currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries.  For more information, visit the company’s website at  www.cescatherapeutics.com.